“…AT-101, an orally bioavailable solvate of [20] ABT-737 and ABT-263 (gossypol served as a lead compound) [2] III. Thiol redox inhibitors Curcumin [26,34,35] Myricetin, quercetin, catechin, pelargonidin, and taxifolin [27] Hydroxychalcone, dihydroxychalcones, chrysin, and apigenin [44] Kaempferol [28] A green tea extract [42] (−)-Epigallocatechin-3-gallate (EGCG) [30,31] EGCG, ECG, catechin, epicatechin, and propyl gallate [32] Theaflavin-3-gallate and theaflavin-3′-gallate [43] A mixture of theaflavin (TF), TF-3-monogallate, TF-3′-monogallate, and TF-3,3′-digallate [33] Hydroxyl-substituted chalcone and chalcone analogs [45] Sigmoidin A and eriodictyol [46] A derivative of xanthohumol [ [64] A polyphenol-rich extract from Semecarpus anacardium nut milk [16] 2-Phenyl-4H-1-benzo-pyran-4-one (a flavone) [60] NV-128 (a derivative of genistein) [54] Hydroxyl-substituted chalcones and cyclic chalcone analogues [45] Dimethoxycurcumin [8] (−)-gossypol (a polyphenolic BH3-mimetic) and acetic acid, proved to be a safe enhancement of the efficacy of the conventional therapy in a murine model of drug-resistant B-cell lymphoma [20]. In the ClinicalTrials.gov database (https://clinicaltrials.gov, website accessed on April 29, 2015), 24 clinical studies are registered for AT-101, including a phase III trial on non-small cell lung cancer.…”